NCT03703271RecruitingPhase 2
Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
A Non-Inferiority Prospective Randomized Multicenter Clinical Control Study of Hysteroscopic Repeat Curettage as the Primal Management of Low-risk Postmolar Gestational Trophoblastic Neoplasia
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
Study of hysteroscopic repeat curettage as the first-line treatment in low-risk postmolar gestational trophoblastic neoplasia compared with the MTX single drug chemotherapy
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 2 Oct 2018
- Start date
- 1 Mar 2019
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Women's Hospital School Of Medicine Zhejiang University
- NCT number
- NCT03703271
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 70
- From 1 Mar 2019 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- With severe or uncontrolled internal disease, unable to receive chemotherapy
Other
- Patients with unconfirmed diagnosis of GTN
- Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT)
- WHO risk score ≥5分
- The diameter of a single metastatic lesion in the lung was ≥2cm
- The number of lung CT metastases was≥ 5
- Concurrently participating in other clinical trials
- Unable or unwilling to sign informed consents
- Unable or unwilling to abide by protocol
Who the study is looking for
- low-risk postmolar gestational trophoblastic neoplasia (GTN)
- World Health Organization(WHO) risk score≤4
- Age≤60 years; female, Chinese women
- Initial treatment
- Performance status: Karnofsky score≥60
- Laboratory tests: WBC≥3.5×10(9)/L, ANC≥1.5×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal,blood urea nitrogen, Cr≤ normal
- Provide written informed consent.
Age in the registry: 12 years to 60 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Weiguo Lv Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.